Slowing aging by purging senescent cells
nytimes.com
nytimes.com
http://www.fightaging.org/archives/2011/11/the-need-for-visi...
"So after Mayo Clinic researchers discovered they could delay degeneration of the tissues in a fast-aging strain of mice by purging senescent cells, they applied to the agency's National Institute on Aging for financing for the next essential step, that of repeating the test in mice with a normal life span. Under the agency's peer review system, panels of fellow experts judge each proposal and assign it a score. On paper, it's hard to think of a better system. But in practice, experts often differ, even on the best proposals, and a single dissenting vote can reduce a proposal's overall score too low to get financed. The Mayo proposal got a less than perfect score, and was denied money. ... Their peer review process is not promoting innovative, high-risk research. ... They were able to get their research started only because private funds were available from the Ellison Medical Foundation, supported by Larry Ellison of the Oracle software company, and from Robert P. Kogod, a philanthropist in Washington. After publication of the Mayo Clinic team's paper in Nature this month, they were approached by the Glenn Foundation, set up by the commodities trader Paul F. Glenn, who has a longstanding interest in aging research. The foundation gave them an unsolicited $60,000 and said it would be around to talk later."
You'll recognize a number of those names as supporters of the SENS Foundation and Methuselah Foundation before it over the past four or five years, having put millions of dollars collectively into the work of those organizations on (a) the basis for rejuvenation biotechnology and (b) what might charitably be looked on as kicking the research community in the pants to make them get on and do the damn job and make some noise about it.
In fact wherever there is somewhat innovative research into aging and longevity - looking at repair, not just trying to find drugs to replicate the effects of calorie restriction and push through the same old tired FDA processes - you'll see many of the same visionary philanthropists behind the scenes.
A related item by Aubrey de Grey on why people with the means are not pumping as much funding as they can into longevity science, given the clear and amazing payoffs:
http://hplusmagazine.com/2011/11/21/why-arent-more-wealthy-p...
The NIH has taken the view that steady, incremental progress is a better use of money than swinging for the fences. While I'm not defending the NIH's decisions, I can understand the reasoning.
And regarding de Grey...well, I can appreciate his contribution to raising awareness. Otherwise, his views are somewhat akin to claiming "Like, what if we are living in the matrix, man?" as "Philosophy".
The press releases make this sound like the sort of research that should be shot to the top of all priorities, but when you really examine it, that assessment doesn't hold up very well. It may still be important, but it isn't as important as the news articles make it sound. The less-than-perfect grading is probably correct.
Now, had they demonstrated mice that lived longer than the core breed after this treatment, I'd be singing a different song.
http://www.fightaging.org/archives/2011/11/a-demonstration-o...
And heavy in depth commentary:
Cell senescence: stay, but your contract won't be renewed
I wonder if it's possible to reactivate a senescent cell by repairing the damage that triggered it in the first place: repair and rejuvenation.
Add: possibly no: "repair to DNA normally take place during DNA replication when cells are dividing, but post-mitotic cells do not divide. The main concern in this instance is not whether there is a decrease in the ability of cells to repair DNA with age, but instead whether post-mitotic cells can themselves repair DNA, if at all they need to"
http://ageing-research.blogspot.com/2008/01/post-mitotic-tis...
Also, is it possible to replace a cell that has already suicided by causing an improvement in conditions that'd ensure a replacement cell isn't tagged with the same fate: reconditioning and recruitment.
I can imagine few things that are more worthwhile (and probably stimulating to work on as well).